

# Corporate Action Notice

March 28, 2017

## Name Change

### VimpelCom Ltd. – Name Change to – VEON Ltd.

Please be advised that VimpelCom Ltd. announced a name change to VEON Ltd. The company's name change is subject to approval at the special general meeting of shareholders to be held on March 30, 2017.

The following identifiers have been assigned:

**Old Common CUSIP : 92719A106**  
**Old Common DR ISIN : US92719A1060**

**New Common CUSIP : 91822M106**  
**New Common DR ISIN : US91822M1062**

**Old Preferred CUSIP : 92719A205**  
**Old Preferred DR ISIN : US92719A2050**

**New Preferred CUSIP : 91822M205**  
**New Preferred DR ISIN : US91822M2052**

**Old RegS CUSIP : 92719A304**  
**Old RegS DR ISIN : US92719A3041**

**New RegS CUSIP : 91822M304**  
**New RegS DR ISIN : US91822M3043**

The effective date for the name change will be March 31, 2017.

DR holders need not take any action. Existing DR certificates will assume the new parameters and will not be subject to a mandatory exchange

---

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

#### NEW YORK

Ravi Davis  
Richard J Maehr  
+ 1 212 815 2267  
adrdesk@bnymellon.com

#### LONDON

Jacek Jankowski  
Vice President  
+ 44 207 163 7427  
jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at [https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset\\_upload\\_file49220\\_197380.pdf](https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf). Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



BNY MELLON